Boundless Bio closed at $2.40 on Nov 4, up 0.84%, 20.0% below its 52-week closing high. Volume of 138.9K shares was 0.83× its 20-day average (close to normal).
Split-adjusted performance: -6.6% over one month, +51.9% over six months, +75.2% over one year.
Short interest was 788.5K shares at the Oct 15 settlement, up 1.3% from the prior report (7.0% of float, 4.6 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| BOLDBoundless Bio | $2.40 | +0.84% | +51.9% | — | — | — | $55.5M | |
| ONCYOncolytics Biotech | $0.4248 | +8.92% | −53.8% | — | — | — | $55.7M | Compare |
| RFLRafael Holdings | $1.07 | −0.93% | −14.4% | −30.3% | −3760.7% | — | $55.8M | Compare |
| TLPHTalphera | $1.05 | +0.96% | +20.7% | — | — | — | $54.5M | Compare |
| HRTXHeron Therapeutics | $0.2986 | +4.88% | −77.2% | +1.3% | −14.6% | — | $56.7M | Compare |
| RNTXRein Therapeutics | $0.6587 | −1.32% | −43.7% | — | — | — | $56.8M | Compare |
| OSTXOS Therapies Incorporated | $1.15 | −0.86% | −33.5% | — | — | — | $53.8M | Compare |
| XLOXilio Therapeutics | $8.71 | +0.35% | +10.3% | +131.2% | −34.1% | — | $57.3M | Compare |
| CTORCitius Oncology | $0.5470 | −0.55% | −39.8% | — | −597.4% | — | $57.9M | Compare |
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
